These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 24941434)

  • 1. Hepatic dysfunction related to thyrotropin receptor antibody in patients with Graves' disease.
    He K; Hu Y; Xu XH; Mao XM
    Exp Clin Endocrinol Diabetes; 2014 Jun; 122(6):368-72. PubMed ID: 24941434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Determination of the levels of anti-thyroid-stimulating hormone receptor antibody with thyroid peroxidase antibody in Omani patients with Graves' disease.
    Alnaqdy A; Al-Maskari M
    Med Princ Pract; 2005; 14(4):209-12. PubMed ID: 15961927
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors of hyperthyroidism with hepatic function injury: a 4-year retrospective study.
    Li C; Tan J; Zhang G; Meng Z; Wang R; Li W; Zheng W
    Horm Metab Res; 2015 Mar; 47(3):209-13. PubMed ID: 24867136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Decreased serum level of IL-7 in patients with active Graves' disease.
    Motylewska E; Nieć M; Siejka A; Komorowski J; Ławnicka H; Świętosławski J; Stępień H
    Cytokine; 2015 Oct; 75(2):373-9. PubMed ID: 26113403
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age Moderates the Impact of TRAbs on Thyroid Hormones and Hepatic Function in Patients with Graves' Disease.
    Guo K; Ling H; Zhou X; Ying C
    Horm Metab Res; 2021 Jul; 53(7):453-460. PubMed ID: 34282596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The association of TSH-receptor antibody with the clinical and laboratory parameters in patients with newly diagnosed Graves' hyperthyroidism: experience from a tertiary referral center including a large number of patients with TSH-receptor antibody-negative patients with Graves' hyperthyroidism.
    Zuhur SS; Bilen O; Aggul H; Topcu B; Celikkol A; Elbuken G
    Endokrynol Pol; 2021; 72(1):14-21. PubMed ID: 32944926
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Similar clinical performance of a novel chimeric thyroid-stimulating hormone receptor bioassay and an automated thyroid-stimulating hormone receptor binding assay in Graves' disease.
    Kamijo K; Murayama H; Uzu T; Togashi K; Olivo PD; Kahaly GJ
    Thyroid; 2011 Dec; 21(12):1295-9. PubMed ID: 22066477
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Binding, stimulating and blocking TSH receptor antibodies to the thyrotropin receptor as predictors of relapse of Graves' disease after withdrawal of antithyroid treatment.
    Quadbeck B; Hoermann R; Hahn S; Roggenbuck U; Mann K; Janssen OE
    Horm Metab Res; 2005 Dec; 37(12):745-50. PubMed ID: 16372228
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IGF1 deficiency in newly diagnosed Graves' disease patients.
    Martin S; Sirbu A; Betivoiu M; Florea S; Barbu C; Fica S
    Hormones (Athens); 2015; 14(4):651-9. PubMed ID: 26188228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bioluminescence assay for thyrotropin receptor antibodies predicts serum thyroid hormone levels in patients with de novo Graves' disease.
    Hovens GC; Buiting AM; Karperien M; Ballieux BE; van der Pluijm G; Pereira AM; Romijn JA; Smit JW
    Clin Endocrinol (Oxf); 2006 Apr; 64(4):429-35. PubMed ID: 16584516
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Distribution of IgG subclasses of TgAb and TPOAb in sera from patients with Graves' disease, Graves' disease plus Hashimoto's thyroiditis and Hashimoto's thyrotoxicosis].
    Yuan S; Yu N; Gao Y; Huang W; He Y; Dong B; Lu G; Li M; Cai X; Peng D; Wang Y; Li T; Huang Y; Gao Y; Guo X; Shi B
    Zhonghua Yi Xue Za Zhi; 2014 Jan; 94(2):110-4. PubMed ID: 24721350
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of new different assay systems for thyrotropin receptor antibodies with reference to thyroid-stimulating antibodies and thyroid stimulation-blocking antibodies in Graves' disease.
    Hirooka Y; Li C; Takagi J; Gotoh M; Habu S; Yasaka-Nomura T; Ishihara R; Nakasone Y; Nakamura R; Morikawa R; Otake K; Nogimori T; Ishizuki Y
    Int J Clin Pharmacol Res; 2004; 24(4):111-6. PubMed ID: 15754915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum and thyroid tissue level of let-7b and their correlation with TRAb in Graves' disease.
    Chen X; Huang F; Qi Y; Zhou M; Yin Q; Peng Y; Zhou Y; Ning G; Wang S
    J Transl Med; 2018 Jul; 16(1):188. PubMed ID: 29976201
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitive thyroid-stimulating antibody assay with high concentrations of polyethylene glycol for the diagnosis of Graves' disease.
    Takasu N; Kamijo K; Sato Y; Yoshimura H; Nagata A; Ochi Y
    Clin Exp Pharmacol Physiol; 2004; 31(5-6):314-9. PubMed ID: 15191404
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Individual outcome monitoring of TSH receptor antibody level for predicting the prognosis of Graves' disease].
    Rink T; Holle LH; Schroth HJ; Garth H
    Nuklearmedizin; 1998 May; 37(3):90-4. PubMed ID: 9604228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between thyrotropin receptor antibody levels and intrathyroid vascularity in patients with Graves' disease.
    Shih SR; Chang JS; Lin LC; Chang YC; Li HY; Lee CY; Chen CM; Chang TC
    Exp Clin Endocrinol Diabetes; 2013 Jan; 121(1):1-5. PubMed ID: 23258570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Th1/Th2 cytokines in patients with Graves' disease with or without ophthalmopathy.
    Esfahanian F; Naimi E; Doroodgar F; Jadali Z
    Iran J Allergy Asthma Immunol; 2013 May; 12(2):168-75. PubMed ID: 23754356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An improved method for the establishment of a model of Graves' disease in BALB/c mice.
    Zheng W; Wang R; Tan J; Li N; Meng Z
    Mol Med Rep; 2017 Apr; 15(4):1471-1478. PubMed ID: 28259898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the 2nd generation radio-receptional assay for anti-TSH receptor antibodies (TRAb) in autoimmune thyroid diseases. Comparison with 1st generation and anti-thyroperoxidase antibodies (AbTPO).
    Giovanella L; Ceriani L; Garancini S
    Q J Nucl Med; 2001 Mar; 45(1):115-9. PubMed ID: 11456370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of Graves' disease: effects of the administration of L-thyroxine associated with methimazole as a single daily dose.
    Perozim LM; Lima N; Knobel M; Cavaliere H; Medeiros-Neto G
    Eur J Med; 1993 Feb; 2(2):70-4. PubMed ID: 8258020
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.